Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

Grants

Funding Acknowledgements

David Ross has received research funding from Novartis and honoraria from Novartis and BMS. Chris Arthur has received research funding from Novartis, BMS and Ariad and honoraria from Novartis, STA, BMS and Pfizer. Kate Burbury has received honoraria from BMS and Novartis and research funding from Ariad. Brian Ko has received honararia from BMS, Pfizer, Novartis, Specialised Therapeutics and Boehringer Ingelheim. Anthony Mills has received honoraria from Novartis, BMS, Specialised Therapeutics and Pfizer. Jake Shortt has received research funding from BMS and honoraria from Novartis and BMS. Karam Kostner has no disclosures relevant to this publication.